⚡️ #CARsgen soumet des applications IND doubles pour le produit #Allogène 💉 #BCMA #CAR_T 🧬 #CT0596

Les demandes visent deux essais cliniques pour le traitement du #MyélomeMultiple 🩸 (R/R) & de la #Leucémie 🩸 des cellules plasmocytaires primaires ( #pPCL)
www.prnewswire.com/news-release...

CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it...

⚡️ #CARsgen a soumis deux demandes d' #IND auprès de la #NMPA pour son produit #Allogénique ciblant #BCMA avec cellules #CAR_T 🧬, #CT0596
Les demandes visent à initier deux essais cliniques de phase Ib/II pour le #MyélomeMultiple R/R et de la #Leucémie #pPCL
www.prnewswire.com/news-release...

CARsgen Advances Innovative CAR-T Therapy CT0596 with Dual IND Submissions CARsgen Therapeutics has made significant strides by submitting dual IND applications for its CAR-T therapy CT0596, targeting critical blood cancers. With promising results already, this therapy may reshape treatment options for patients.

CARsgen Advances Innovative CAR-T Therapy CT0596 with Dual IND Submissions #China #Shanghai #CAR-T_therapy #CARsgen_Therapeutics #CT0596

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that...

⚡️ #CARsgen 🇨🇳 annonce les données de la thérapie #Allogénique 💉 par cellules #BCMA #CAR_T 🧬 #CT0596 pour le #MyélomeMultiple 🩸 R/R lors de la réunion annuelle de l’ #ASH2025
www.prnewswire.com/news-release...

CARsgen Presents Promising Results for Allogeneic CAR-T Therapy at ASH Annual Meeting 2025 CARsgen Therapeutics reveals encouraging clinical data for CT0596, a novel allogeneic CAR-T therapy for multiple myeloma, at ASH 2025.

CARsgen Presents Promising Results for Allogeneic CAR-T Therapy at ASH Annual Meeting 2025 #China #Shanghai #CAR-T_therapy #CARsgen #CT0596

CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces...

✨ #CARsgen annonce des données positives pour les produits #CAR_T 🧬 #Allogéniques #CT0596 ciblant #BCMA pour le #MyélomeMultiple 🩸 R/R, et pour #CT1190B, un produit candidat CAR-T allogénique ciblant #CD19/#CD20 pour le #Lymphome 🩸 non hodgkinien #LNH R/R.
www.prnewswire.com/news-release...

CARsgen Therapeutics Announces Promising Results for CAR-T Therapies CT0596 and CT1190B CARsgen Therapeutics reveals encouraging clinical outcomes for its allogeneic CAR-T products CT0596 and CT1190B, targeting multiple myeloma and non-Hodgkin lymphoma, respectively.

CARsgen Therapeutics Announces Promising Results for CAR-T Therapies CT0596 and CT1190B #China #Shanghai #CARsgen_Therapeutics #CT0596 #CT1190B

New CAR-T Therapy CT0596 Shows Promise for Treating Primary Plasma Cell Leukemia CARsgen's CT0596, an allogeneic BCMA CAR-T therapy, shows promise in treating relapsed/refractory primary plasma cell leukemia, offering hope for patients.

New CAR-T Therapy CT0596 Shows Promise for Treating Primary Plasma Cell Leukemia #China #Shanghai #CARsgen #CT0596 #pPCL

CARsgen's CT0596 Shows Encouraging Results in Preliminary Clinical Trials for BCMA CAR-T Therapy CARsgen Therapeutics announces preliminary clinical data for CT0596, indicating its potential effectiveness and safety in treating relapsed multiple myeloma.

CARsgen's CT0596 Shows Encouraging Results in Preliminary Clinical Trials for BCMA CAR-T Therapy #China #Shanghai #CAR-T_therapy #CARsgen #CT0596